NCT05912621View on ClinicalTrials.gov

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2029

Conditions
ObesityOverweight and ObesityOverweight
Interventions
DRUG

Tirzepatide

Tirzepatide dose is titrated up by 2.5 mg every four weeks as per below, starting with 2.5 mg weekly and maxing out at 15 mg.

Trial Locations (1)

94305

RECRUITING

Clinical and Translational Research Unit, Palo Alto

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Stanford University

OTHER